Allos Therapeutics to Report Fourth Quarter and Full Year 2010 Results on March 3, 2011
February 17 2011 - 9:00AM
Business Wire
Allos Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics, today announced that the
Company will report its financial results for the fourth quarter
and full year ended December 31, 2010 on Thursday, March 3, 2011,
after the financial markets close. Following the release of the
financial results, Allos management will provide a corporate update
and review of the fourth quarter and full year 2010 results via
audio webcast conference call on Thursday, March 3, 2011, at 4:30
p.m. Eastern Time (ET).
To access the live audio webcast or the subsequent archived
recording, visit the “Investors - Presentations and Events” section
of the Company’s website at www.allos.com. Alternatively, callers
may participate in the conference call by dialing 1-800-762-8779
(U.S.) or +480-629-9771 (Canada and international). Participants
should reference the Allos Therapeutics conference call. Webcast
and telephone replays of the conference call will be available
approximately two hours after the completion of the call through
March 17, 2011. To access the replay, callers should dial
1-800-406-7325 (domestic) or +1-303-590-3030 (international) and
use passcode 4410612#.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics. Allos is currently focused on
the development and commercialization of FOLOTYN® (pralatrexate
injection), a folate analogue metabolic inhibitor. FOLOTYN is the
first and only drug approved in the U.S. for the treatment of
patients with relapsed or refractory peripheral T-cell lymphoma.
Allos is also developing FOLOTYN in other hematologic malignancies
and solid tumors. Allos retains exclusive worldwide rights to
FOLOTYN for all indications. Allos is headquartered in Westminster,
CO. For additional information, please visit www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties.
Additional information concerning these forward-looking statements
and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements
is contained in the "Risk Factors" section of the Company's
Quarterly Report on Form 10-Q for the quarter ended September 30,
2010 and in the Company's other periodic reports and filings with
the Securities and Exchange Commission. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in the presentation. All forward-looking
statements are based on information currently available to the
Company on the date thereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to
reflect events or circumstances after the date of these
presentations, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Sep 2023 to Sep 2024